UBS Assumes Pfizer at Neutral, Lowers Price Target of $34
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Colin Bristow has assumed Pfizer (NYSE:PFE) with a Neutral rating and lowered the price target to $34.
October 20, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pfizer's price target has been lowered to $34 by UBS analyst Colin Bristow, who has given the company a Neutral rating.
The lowering of Pfizer's price target by UBS indicates a potential decrease in the stock's value. The Neutral rating suggests that the stock is not expected to outperform the market in the near term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100